|
Market Closed -
Nasdaq
21:00:00 07/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.430 USD | -2.05% |
|
-10.62% | +4.38% |
Company Valuation: Allogene Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,126 | 907.1 | 540.2 | 446.6 | 307.9 | 494.1 | - | - |
| Change | - | -57.34% | -40.45% | -17.32% | -31.06% | 60.47% | - | - |
| Enterprise Value (EV) 1 | 1,317 | 330.6 | 91.47 | 234.8 | 347 | 297.5 | 343.9 | 163 |
| Change | - | -74.89% | -72.33% | 156.69% | 47.8% | -14.27% | 15.58% | -52.61% |
| P/E | -7.89x | -2.71x | -1.54x | -1.61x | -1.57x | -2.37x | -2.23x | -2.56x |
| PBR | 2.32x | 1.36x | 1.06x | 1.07x | 1.07x | 1.23x | 2.48x | 1.11x |
| PEG | - | -0.1x | 0.16x | 0x | 0x | 0.1x | -0.35x | 0.2x |
| Capitalization / Revenue | 55.2x | 3,733x | 5,686x | 20,300x | - | 145x | 40.9x | 5.84x |
| EV / Revenue | 34.2x | 1,361x | 963x | 10,673x | - | 87.5x | 28.5x | 1.93x |
| EV / EBITDA | -5.37x | -1.03x | -0.29x | -0.96x | -1.76x | -1.49x | -1.43x | -0.6x |
| EV / EBIT | -5.15x | -0.99x | -0.28x | -0.91x | -1.66x | -1.49x | -1.48x | -0.75x |
| EV / FCF | -6.38x | -1.46x | -0.38x | -1.17x | -2.32x | -2.36x | -2.36x | -1.3x |
| FCF Yield | -15.7% | -68.3% | -262% | -85.6% | -43.1% | -42.5% | -42.5% | -77.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.89 | -2.32 | -2.09 | -1.32 | -0.87 | -0.6036 | -0.642 | -0.5596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.49 | 0.243 | 0.095 | 0.022 | - | 3.4 | 12.09 | 84.64 |
| EBITDA 1 | -245.3 | -321.2 | -313.5 | -243.8 | -197 | -200.2 | -239.7 | -271.5 |
| EBIT 1 | -255.8 | -335.4 | -327.7 | -257.5 | -209.3 | -199.1 | -232.9 | -218.3 |
| Net income 1 | -257 | -332.6 | -327.3 | -257.6 | -190.9 | -185.1 | -219.8 | -212.4 |
| Net Debt 1 | -809.5 | -576.5 | -448.7 | -211.8 | 39.16 | -196.5 | -150.2 | -331.1 |
| Reference price 2 | 14.920 | 6.290 | 3.210 | 2.130 | 1.370 | 1.430 | 1.430 | 1.430 |
| Nbr of stocks (in thousands) | 142,516 | 144,210 | 168,277 | 209,672 | 224,730 | 345,491 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 14/03/24 | 13/03/25 | 12/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.42x | 90.56x | -1.54x | -.--% | 504M | |
| 21.73x | 7.77x | 15.6x | 1.37% | 74.69B | |
| 30.56x | 8.79x | 27.4x | 0.04% | 58.81B | |
| 33.6x | 6.04x | 18.08x | 0.96% | 48.45B | |
| -20.7x | 214.73x | -22.18x | -.--% | 42.84B | |
| 33.49x | 3.25x | 14.04x | -.--% | 42.79B | |
| 48.17x | 5.48x | 30.1x | -.--% | 41.25B | |
| 27.6x | 7.84x | 20.39x | 0.41% | 31.13B | |
| 35.01x | 7.5x | 19.48x | -.--% | 30.28B | |
| -14.91x | 5.52x | -6.94x | -.--% | 24.05B | |
| Average | 19.21x | 35.75x | 11.44x | 0.28% | 39.48B | |
| Weighted average by Cap. | 23.16x | 29.39x | 14.19x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALLO Stock
- Valuation Allogene Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
